Company Overview and News

 
ILFS Transport, Avanti Feeds, Suzlon, Balrampur Chini top gainers among BSE Group A stocks

2018-09-17 moneycontrol
The Indian benchmark indices continued to trade in the red on Monday afternoon with the Nifty50 down 142 points while the Sensex was trading lower by 504 points at 37,586.
BALRAMCHIN SUZLON ZODIACLOTH AVANTI MONSANTO 507490 512573 532667 513023 524084 521163 500038 RANASUG SUEL NBVENTURES

 
Sugar stocks extend gains, zoom 20% after government hikes ethanol price by 25%

2018-09-14 moneycontrol
Sugar stocks are rallying this Friday afternoon and have given robust gains after the government approved hiking the price of ethanol produced directly from sugarcane juice for blending in petrol by 25 percent.
MAWANASUG BALRAMCHIN 523371 532670 SAKHTISUG 507490 500038 RENUKA RANASUG 507315

 
Sugar stocks rally 20% as govt raises ethanol price

2018-09-14 thehindubusinessline
Shares of sugar companies jumped as much as 20 per cent as the government has raised the ethanol price for blending in petrol by 25 per cent.
THIRUSUGAR UTTAMSUGAR 532729 500119 507490 BANARISUG 532610 500041 DWARKESH 507450 532460 SAKHTISUG PONNIERODE RANASUG 507315 DHAMPURSUG

 
Rana Sugars Limited - Book Closure

2018-09-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
507490 RANASUG

 
Rana Sugars Limited - Shareholders meeting

2018-09-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
507490 RANASUG

 
Rana Sugars Limited - Outcome of Board Meeting

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
507490 RANASUG

 
Rana Sugars Limited - Clarification - Financial Results

2018-06-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
507490 RANASUG

 
Rana Sugars Limited - Clarification

2018-06-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
507490 RANASUG

 
Rana Sugars Limited - Outcome of Board Meeting

2018-06-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
507490 RANASUG

 
Rana Sugars Limited - Financial Result Updates

2018-06-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
507490 RANASUG

26
Podcast | Nifty holds above 10,700 levels; Sensex ends flat on US Fed jitters

2018-05-02 moneycontrol
Indian markets closed mixed on Wednesday ahead of the US Federal Reserve outcome. In all likelihood, the US Federal Reserve might stay put but a future commentary on rates is likely to chart the direction of markets across the globe including India.
500820 HCTHY ASIANPAINT 532215 500470 523371 AXISBANK 532281 RANASUG INDIGO AXB KMBKY IBN 507490 539448 AXBKY MAWANASUG AXBA ICICIBANK TTST TATASTEEL TATLY 532174 HCLTECH KOTAKBANK 534809 500247 PCJEWELLER

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...